<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03113162</url>
  </required_header>
  <id_info>
    <org_study_id>MMCIRB 2015-024</org_study_id>
    <nct_id>NCT03113162</nct_id>
  </id_info>
  <brief_title>Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis</brief_title>
  <official_title>Evaluation of the Safety and Efficacy of Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Makati Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Makati Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a patient-sponsored study that evaluates the safety and efficacy of reduced-intensity
      immunoablation followed by a single dose autologous hematopoetic stem cell transplantation in
      patients diagnosed with multiple sclerosis. Patients are followed-up after 1 month, 3 months,
      6 months and 12 months post-transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 29, 2015</start_date>
  <completion_date type="Anticipated">May 29, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 29, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Type, occurence, severity, timing, seriousness and relatedness of adverse events and laboratory abnormalities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: EDSS Score</measure>
    <time_frame>1 month post-infusion, 3 months month post-infusion, 6 months month post-infusion, 12 months month post-infusion</time_frame>
    <description>Measurement of disease progression by change in baseline of EDSS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: RAND-36 Score</measure>
    <time_frame>1 month post-infusion, 3 months month post-infusion, 6 months month post-infusion, 12 months month post-infusion</time_frame>
    <description>Measurement of Quality of Life by change in baseline of RAND-36 score</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Autologous Hematopoietic Stem Cell with BEAM Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous HSCT following Reduced-Intensity BEAM Regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Hematopoietic Stem Cell</intervention_name>
    <arm_group_label>Autologous Hematopoietic Stem Cell with BEAM Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BEAM Regimen</intervention_name>
    <description>Reduced-intensity BEAM for Immunoablation</description>
    <arm_group_label>Autologous Hematopoietic Stem Cell with BEAM Regimen</arm_group_label>
    <other_name>BCNU, Etoposide, Cytarabine, Melphalan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with progressive multiple sclerosis with or without relapses

          -  EDSS score between 1.5 and 7.0, including documented rapid progression over the
             previous year unresponsive to conventional therapies or no available treatment options

          -  Aged between 18 and 60 with a history of at least one enhancing lesion on brain MRI

          -  With absolute neutrophil count ≥ 1,000/mm^3, platelet count ≥ 100,000/mm^3 and
             hemoglobin ≥ 9.0 g/dL

        Exclusion Criteria:

          -  Patients with cardiac, renal, pulmonary, hepatic, or other organ impairment that would
             limit their ability to receive dose-intensive immunosuppressive therapy, high-dose
             chemotherapy, and/or Autologous HSCT

          -  Patients with any active or chronic infection e.g. uncontrolled viral, fungal, or
             bacterial infection

          -  Uncontrolled diabetes

          -  Patients who are seropositive for HIV1, HIV2, Hepatitis B Surface Antigen, and
             Hepatitis C

          -  Patients whose life expectancy is severely limited by another illness

          -  Patients with evidence of myelodysplasia or other non-autoimmune cytopenia

          -  Patients having received a cytotoxic agent within one month prior to this study

          -  Patients who are pregnant or at risk of pregnancy, including those unwilling to
             practice

          -  Patients with psychiatric illness, mental deficiency, or cognitive dysfunction

          -  Patients unable to give written informed consent in accordance with research ethics
             board guidelines
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darwin Albert A Dasig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Makati Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marviel T Berboso, RN</last_name>
    <phone>8888999</phone>
    <phone_ext>3613</phone_ext>
    <email>Inquiry.CTC@makatimed.net.ph</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jose Maria C Avila, MD</last_name>
    <phone>8888999</phone>
    <phone_ext>3614</phone_ext>
    <email>stemcell@makatimed.net.ph</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Makati Medical Center</name>
      <address>
        <city>Makati</city>
        <zip>1229</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marviel T Berboso, RN</last_name>
      <phone>8888999</phone>
      <phone_ext>3613</phone_ext>
      <email>Inquiry.CTC@makatimed.net.ph</email>
    </contact>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <reference>
    <citation>Akkök CA, Liseth K, Hervig T, Ryningen A, Bruserud Ø, Ersvaer E. Use of different DMSO concentrations for cryopreservation of autologous peripheral blood stem cell grafts does not have any major impact on levels of leukocyte- and platelet-derived soluble mediators. Cytotherapy. 2009;11(6):749-60. doi: 10.3109/14653240902980443.</citation>
    <PMID>19878061</PMID>
  </reference>
  <reference>
    <citation>Appelbaum FR, Bacigalupo A, Soiffer R. Anti-T cell antibodies as part of the preparative regimen in hematopoietic cell transplantation--a debate. Biol Blood Marrow Transplant. 2012 Jan;18(1 Suppl):S111-5. doi: 10.1016/j.bbmt.2011.11.002. Review.</citation>
    <PMID>22226093</PMID>
  </reference>
  <reference>
    <citation>Burt RK, Balabanov R, Han X, Sharrack B, Morgan A, Quigley K, Yaung K, Helenowski IB, Jovanovic B, Spahovic D, Arnautovic I, Lee DC, Benefield BC, Futterer S, Oliveira MC, Burman J. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. JAMA. 2015 Jan 20;313(3):275-84. doi: 10.1001/jama.2014.17986.</citation>
    <PMID>25602998</PMID>
  </reference>
  <reference>
    <citation>Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G, Oyama Y, Russell EJ, Stern J, Muraro P, Rose J, Testori A, Bucha J, Jovanovic B, Milanetti F, Storek J, Voltarelli JC, Burns WH. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol. 2009 Mar;8(3):244-53. doi: 10.1016/S1474-4422(09)70017-1. Epub 2009 Jan 29. Erratum in: Lancet Neurol. 2009 Apr;8(4):309. Stefosky, Dusan [corrected to Stefoski, Dusan].</citation>
    <PMID>19186105</PMID>
  </reference>
  <reference>
    <citation>Brück W. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J Neurol. 2005 Nov;252 Suppl 5:v3-9. Review.</citation>
    <PMID>16254699</PMID>
  </reference>
  <reference>
    <citation>von Büdingen HC, Kuo TC, Sirota M, van Belle CJ, Apeltsin L, Glanville J, Cree BA, Gourraud PA, Schwartzburg A, Huerta G, Telman D, Sundar PD, Casey T, Cox DR, Hauser SL. B cell exchange across the blood-brain barrier in multiple sclerosis. J Clin Invest. 2012 Dec;122(12):4533-43. doi: 10.1172/JCI63842. Epub 2012 Nov 19.</citation>
    <PMID>23160197</PMID>
  </reference>
  <reference>
    <citation>Cabezudo E, Dalmases C, Ruz M, Sanchez JA, Torrico C, Sola C, Querol S, García J. Leukapheresis components may be cryopreserved at high cell concentrations without additional loss of HPC function. Transfusion. 2000 Oct;40(10):1223-7.</citation>
    <PMID>11061859</PMID>
  </reference>
  <reference>
    <citation>Costantino CM, Baecher-Allan C, Hafler DA. Multiple sclerosis and regulatory T cells. J Clin Immunol. 2008 Nov;28(6):697-706. doi: 10.1007/s10875-008-9236-x. Epub 2008 Sep 2. Review.</citation>
    <PMID>18763026</PMID>
  </reference>
  <reference>
    <citation>De Boer F, Dräger AM, Van der Wall E, Pinedo HM, Schuurhuis GJ. Changes in L-selectin expression on CD34-positive cells upon cryopreservation of peripheral blood stem cell transplants. Bone Marrow Transplant. 1998 Dec;22(11):1103-10.</citation>
    <PMID>9877274</PMID>
  </reference>
  <reference>
    <citation>Farge D, Labopin M, Tyndall A, Fassas A, Mancardi GL, Van Laar J, Ouyang J, Kozak T, Moore J, Kötter I, Chesnel V, Marmont A, Gratwohl A, Saccardi R. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica. 2010 Feb;95(2):284-92. doi: 10.3324/haematol.2009.013458. Epub 2009 Sep 22.</citation>
    <PMID>19773265</PMID>
  </reference>
  <reference>
    <citation>Fassas A, Anagnostopoulos A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V, Tsompanakou A. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant. 1997 Oct;20(8):631-8.</citation>
    <PMID>9383225</PMID>
  </reference>
  <reference>
    <citation>Fassas A, Kimiskidis VK. Autologous hemopoietic stem cell transplantation in the treatment of multiple sclerosis: rationale and clinical experience. J Neurol Sci. 2004 Aug 15;223(1):53-8. Review.</citation>
    <PMID>15261561</PMID>
  </reference>
  <reference>
    <citation>Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Lassmann H. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009 May;132(Pt 5):1175-89. doi: 10.1093/brain/awp070. Epub 2009 Mar 31.</citation>
    <PMID>19339255</PMID>
  </reference>
  <reference>
    <citation>Iannalfi A, Bambi F, Tintori V, Lacitignola L, Bernini G, Mariani MP, Sanvito MC, Pagliai F, Brandigi F, Muscarella E, Tapinassi F, Faulkner L. Peripheral blood progenitor uncontrolled-rate freezing: a single pediatric center experience. Transfusion. 2007 Dec;47(12):2202-6. Epub 2007 Aug 21.</citation>
    <PMID>17714421</PMID>
  </reference>
  <reference>
    <citation>Mancardi GL, Sormani MP, Gualandi F, Saiz A, Carreras E, Merelli E, Donelli A, Lugaresi A, Di Bartolomeo P, Rottoli MR, Rambaldi A, Amato MP, Massacesi L, Di Gioia M, Vuolo L, Currò D, Roccatagliata L, Filippi M, Aguglia U, Iacopino P, Farge D, Saccardi R; ASTIMS Haemato-Neurological Collaborative Group, On behalf of the Autoimmune Disease Working Party (ADWP) of the European Group for Blood and Marrow Transplantation (EBMT); ASTIMS Haemato-Neurological Collaborative Group On behalf of the Autoimmune Disease Working Party ADWP of the European Group for Blood and Marrow Transplantation EBMT. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology. 2015 Mar 10;84(10):981-8. doi: 10.1212/WNL.0000000000001329. Epub 2015 Feb 11.</citation>
    <PMID>25672923</PMID>
  </reference>
  <reference>
    <citation>Passweg JR, Baldomero H, Bregni M, Cesaro S, Dreger P, Duarte RF, Falkenburg JH, Kröger N, Farge-Bancel D, Gaspar HB, Marsh J, Mohty M, Peters C, Sureda A, Velardi A, Ruiz de Elvira C, Madrigal A; European Group for Blood and Marrow Transplantation. Hematopoietic SCT in Europe: data and trends in 2011. Bone Marrow Transplant. 2013 Sep;48(9):1161-7. doi: 10.1038/bmt.2013.51. Epub 2013 Apr 15.</citation>
    <PMID>23584439</PMID>
  </reference>
  <reference>
    <citation>Reich-Slotky R, Colovai AI, Semidei-Pomales M, Patel N, Cairo M, Jhang J, Schwartz J. Determining post-thaw CD34+ cell dose of cryopreserved haematopoietic progenitor cells demonstrates high recovery and confirms their integrity. Vox Sang. 2008 May;94(4):351-7. doi: 10.1111/j.1423-0410.2007.001028.x. Epub 2008 Jan 2.</citation>
    <PMID>18179677</PMID>
  </reference>
  <reference>
    <citation>Shevchenko JL, Kuznetsov AN, Ionova TI, Melnichenko VY, Fedorenko DA, Kartashov AV, Kurbatova KA, Gorodokin GI, Novik AA. Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis. Exp Hematol. 2012 Nov;40(11):892-8. doi: 10.1016/j.exphem.2012.07.003. Epub 2012 Jul 4.</citation>
    <PMID>22771495</PMID>
  </reference>
  <reference>
    <citation>Snowden JA, Saccardi R, Allez M, Ardizzone S, Arnold R, Cervera R, Denton C, Hawkey C, Labopin M, Mancardi G, Martin R, Moore JJ, Passweg J, Peters C, Rabusin M, Rovira M, van Laar JM, Farge D; EBMT Autoimmune Disease Working Party (ADWP); Paediatric Diseases Working Party (PDWP). Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2012 Jun;47(6):770-90. doi: 10.1038/bmt.2011.185. Epub 2011 Oct 17.</citation>
    <PMID>22002489</PMID>
  </reference>
  <reference>
    <citation>Steinman L. A molecular trio in relapse and remission in multiple sclerosis. Nat Rev Immunol. 2009 Jun;9(6):440-7. doi: 10.1038/nri2548. Review.</citation>
    <PMID>19444308</PMID>
  </reference>
  <reference>
    <citation>Zozulya AL, Wiendl H. The role of regulatory T cells in multiple sclerosis. Nat Clin Pract Neurol. 2008 Jul;4(7):384-98. doi: 10.1038/ncpneuro0832. Epub 2008 Jun 24. Review.</citation>
    <PMID>18578001</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Makati Medical Center</investigator_affiliation>
    <investigator_full_name>Darwin A. Dasig</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>multiple sclerosis</keyword>
  <keyword>HSCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

